At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 81 enrolled
Drug / intervention
NuvaRingdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity
In Brief
A Phase 4 clinical trial evaluating NuvaRing for Bacterial Vaginosis. Completed, enrolled 81 participants across 1 site.
Detailed Summary
To assess potential benefits associated with both intermittent (use for 3 weeks, remove for 1 week, as defined in the package insert) and continuous (use for 4 weeks, then replace) CVR use among women either with BV or at high risk for BV. The investigators will also recruit women who are HSV2-infected.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Vaginosis
CountriesUnited States
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartMar 2016
Primary CompletionNov 2021
TodayJul 2026
First PostedMay 4, 2015
Enrollment StartMar 1, 2016
Primary CompletionNov 1, 2021
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 11.2 years ago
Interventions
NuvaRingdrug